R E S U LT S -C o m p a red with the pain VAS scores before active (6.2 ± 1.0) and sham (6.4 ± 0.9) treatments, pain scores after treatment were reduced to 2.5 ± 0.8 and 6.3 ± 1.1, re s p e c t i v e l y. With active PENS treatment, the VAS activity and sleep scores were significantly improved fro m 5.2 ± 1.0 and 5.8 ± 1.3 to 7.9 ± 1.0 and 8.3 ± 0.7, re s p e c t i v e l y. The VAS scores for pain, activi t y, and sleep were unchanged from baseline values after the sham treatments. Patients' daily oral nonopioid analgesic re q u i rements decreased by 49 and 14% after active and sham PENS t reatments, re s p e c t i v e l y. The post-treatment physical and mental components of the SF-36, the BDI, and the POMS all showed a significantly greater improvement with active versus sham t reatments. Active PENS treatment improved the neuropathic pain symptoms in all patients.
P
eripheral neuropathy is the most common complication of type 2 diabetes, occurs in the distal extremities, and typically affects the sensory, motor, and autonomic systems (1,2). In diabetic patients, c h ronic hyperglycemia can produce neuropathic changes that affect peripheral nerv e function and produce extremity pain (3, 4) . The persistence of these painful symptoms can interf e re with the patient' s physical activity and sleep pattern .
Conventional pharmacotherapy for painful diabetic neuropathy remains larg e l y symptomatic. Analgesics, tricyclic antidep ressants, and anticonvulsants are the mainstays of therapy (5). Nonpharm a c ological therapies such as transcutaneous electrical nerve stimulation (TENS) (6), a c u p u n c t u re (7), and spinal cord stimulation (8) have also been used successfully to alleviate the pain and discomfort associated with peripheral neuro p a t h y. Perc u t a n e o u s electrical nerve stimulation (PENS) is a novel electroanalgesic therapy that combines the advantages of both TENS and e l e c t ro a c u p u n c t u re by using perc u t aneously placed disposable acupuncturelike needle probes to stimulate peripheral s e n s o ry nerves innervating the region of n e u ropathic pain. This therapy has re c e n t l y been re p o rted to be highly effective in the s h o rt -t e rm management of a wide variety of acute and chronic pain syndromes (9-13).
The present randomized sham-cont rolled crossover study was designed to evaluate the effectiveness of PENS therapy in diabetic patients with peripheral neuropathic pain. In addition to examining the acute analgesic effects of PENS, changes in physical activity, quality of sleep, and re q u i rements for analgesic medication were examined during a 3-week treatment period.
RESEARCH DESIGN AND M E T H O D S

Study patients
After local institutional review board a p p roval and after patients gave their written i n f o rmed consent, 50 adult diabetic patients (28 women and 22 men), ranging in age f rom 34 to 71 years (means ± SD 55 ± 9 O B J E C T I V E -To evaluate the use of percutaneous electrical nerve stimulation (PENS) in the management of patients with painful diabetic peripheral neuro p a t h y.
RESEARCH DESIGN AND METHODS
-A total of 50 adult patients with type 2 diabetes and peripheral neuropathic pain of 6 months duration involving the lower extre m i t i e s w e re randomly assigned to receive active PENS (needles with electrical stimulation at an alternating frequency of 15 and 30 Hz) and sham (needles only) treatments for 3 weeks. Each series of treatments was administered for 30 min three times a week according to a standardized protocol. After a 1-week washout period, all patients were subsequently switched to the other m o d a l i t y. A 10-cm visual analog scale (VAS) was used to assess pain, physical activity, and quality of sleep before each session. The changes in VAS scores and daily re q u i rements for oral analgesic medication were determined during each 3-week treatment period. Patients completed the MOS 36-Item Short -F o rm Health Survey (SF-36), the Beck Depression Inventory (BDI), and the Profile of Mood States (POMS) before and after completion of each treatment modali t y. At the end of the crossover study, a patient pre f e rence questionnaire was used to compare the effectiveness of the two modalities.
Electroanalgesia with PENS for neuropathic pain years) and in body weight from 46 to 113 kg (70 ± 17 kg) were enrolled in this sham-cont rolled investigator-blinded crossover study. The patients had longstanding type 2 diabetes associated with painful peripheral neuropathic symptoms of 6 months (18 ± 7) duration involving both lower extre m i t i e s . The study patients were re f e rred from the diabetes clinic with a diagnosis of peripheral n e u ropathy confirmed by an abnorm a l n e rve conduction study. These patients complained of burning pain with paresthesia in both legs. Neurological examination of the patients revealed sensory abnormalities in both lower extremities. Exclusion criteria included pre g n a n c y, cardiac arrhythmias or c a rdiac pacemakers, infection or gangre n e , h i s t o ry of vascular insufficiency in the legs, d rug or alcohol abuse, psychiatric disease, major organ disease, radicular pain (sciatica), psychiatric disease, and inability to complete the psychological assessment f o rms re l i a b l y. Patients receiving stero i d s , dilantin, or chemotherapeutic agents were also excluded. All patients were stable re g a rding control of their diabetes, and their medical management was unchanged during the study period. The patients were i n s t ructed to use their current nonopioid analgesic medications on an as-needed basis.
Study design
The patients were randomly assigned to receive active PENS (needles with electrical stimulation) or sham PENS tre a t m e n t (needles only). The crossover study design mandated a 1-week re c o v e ry (washout) period after completing the initial series of t reatments. The protocol also stipulated 30 min of active or sham electrical stimulation t reatment three times a week for 3 consecutive weeks. Each treatment session re q u i red placement of 10 32-gauge (0.2-mm) stainless steel acupuncture-like needle p robes (ITO, Tokyo, Japan) to a depth of 1-3 cm into the soft tissue and/or muscle in the leg and foot bilaterally as illustrated in Fig. 1A -C. The 10 needle probes were connected to five bipolar leads from an investigational (i.e., not approved by the U.S. Food and Drug Administration) low-output electrical generator. These probes were stimulated at alternating frequencies of 15 and 30 Hz every 3 s or at 0 Hz for the active and sham treatments, re s p e c t i v e l y. The generator produced a maximum of 25 m a m p h e res electrical stimulation with a biphasic square-wave pattern and a pulse width of 0.5 ms in a continuous duty cycle. The intensity of the electrical stimulation was adjusted to the highest tolerable level without producing muscle contractions.
B e f o re initiating either tre a t m e n t m o d a l i t y, patients completed a baseline psychological assessment. Both the Physical Component Summary (PCS) and the Mental Component Summary (MCS) scores of the MOS 36-Item Short -F o rm Health Survey (SF-36) (14) were determined 24 h b e f o re the first treatment and were re p e a t e d 48 h after completing the 3-week tre a tment session with each modality. The Beck D e p ression Inventory (BDI) (15) and the P rofile of Mood Status (POMS) (16) were also administered at these same three time points. As a result of questionnaire completion problems, only 46 BDI and 44 POMS tests were analyzed. For all other m e a s u res, data from all 50 subjects were analyzed. Before the first treatment session, all patients were asked to re c o rd their baseline levels of pain, physical activity, and quality of sleep by using three separate 10-cm visual analog scales (VASs), where 0 = minimal (lowest) and 10 = maximal (highest). In addition, each patient was asked to re c o rd the number of doses of oral analgesic medication taken each day. Repeat VAS assessments of pain, activity, and sleep w e re perf o rmed before each treatment session, after each week of treatment, and again at the end of the 3-week tre a t m e n t period with each modality. Daily oral analgesic re q u i rements were re c o rded in the p a t i e n t ' s diary. At 24 h after the final tre a tment session, each patient completed a q u e s t i o n n a i re assessing the relative eff e ctiveness of the two treatment modalities.
Statistical analysis
The NCSS software package (Version 6.0.1 for Windows, Kaysville, UT) was used for all statistical analyses. An a priori power analysis with = 0.05 and = 0.10 (power = 90%) determined that a group size of 40 should be adequate to demonstrate a 25% change in the VAS pain scores between the two treatment modalities. The changes in the VAS scores and oral analgesic medications over time were analyzed by using repeated measures of analyses of variance and Student' s t test. Analysis of discrete data was perf o rmed by using the 2 t e s t . Changes and diff e rences in the psychological assessment were analyzed by using t tests. Data are means ± SD and perc e n t a g e s , and P values 0.05 were considered statistically significant.
R E S U LT S -
The demographic characteristics and treatment effects after the initial 3-week study period are summarized in Table 1 . The post-treatment VAS scores for e x t remity pain, physical activity, and quality of sleep were significantly impro v e d after each week of PENS treatment comp a red with baseline values (P 0.05), but no significant changes were evident after the sham treatments (Table 1 ). The overall p e rcentage reduction in pain after the 3 -week treatment with active PENS (56 ± 17%) was significantly greater than with sham (14 ± 11%) treatments (Table 2) . S i m i l a r l y, the overall average perc e n t a g e i n c reases in physical activity and quality of sleep were also significantly higher after active PENS (48 ± 19 and 41 ± 22%, respectively) compared with sham tre a tments (13 ± 16 and 11 ± 13%, re s p e ctively) (P 0.05). More o v e r, a cumulative e ffect of PENS therapy was noted during the course of the 3-week treatment block.
Evaluation of pre t reatment SF-36 values suggested that the study population had significantly lower health-related score s c o m p a red with the general population. The p restudy scores were 31.2 ± 7.3 and 41 ± 5.8 for the PCS and MCS, re s p e c t i v e l y, comp a red with the general population norm of 50. With PENS therapy, the SF-36 score s w e re significantly improved compared with the prestudy scores for both the PCS (36.8 ± 6.7) and MCS (43.9 ± 5.6) components (P 0.01). Although the sham tre a t m e n t s also produced an improvement in the S F -3 6 re g a rding both PCS (32.4 ± 7.5) and MCS (42 ± 5.5) scores (P 0.05), the eff e c t was significantly less than with active PENS therapy (P 0 . 0 5 ) .
Analysis of the pre t reatment BDI score s indicated that the study population had a mean depression level of 30.2 ± 11.6, which reflects a severe level of depre s s i o n . The post-PENS treatment BDI score s revealed a significant improvement in the level of depression (8.1 ± 4.6) relative to the p re t reatment score (P 0.01). Although the post-sham treatment BDI score was also significantly decreased compared with the prestudy baseline value (20.7 ± 8.2), this level is still in the moderately depre s s e d range. Finally, a comparative analysis revealed that the decrease in the BDI score s was significantly greater after PENS versus sham treatments (P 0 0 1 ) .
The overall results of the POMS evaluation are summarized in Table 3 . A multivariate analysis of variance revealed a significant multivariate effect (Hotelling' s T 2 revealed P 0.01) that justified univariate analyses of the individual POMS m e a s u res. These t tests revealed that, re l ative to pre t reatment values, the postactive and post-sham PENS treatments displayed significant improvement on all POMS meas u res except for the vigor activity measure . M o re import a n t l y, the postactive PENS t reatment was associated with gre a t e r d e c reases on all POMS measures relative to the post-sham treatment (P 0 . 0 5 ) .
In addition to its salutary analgesic e ffects, active PENS treatments significantly DIABETES CARE, VOLUME 23, NUMBER 3, MARCH 2000 367 (years) 9 ± 2 10 ± 3 Duration of symptomatic 17 ± 6 19 ± 8 n e u ropathy (months) Pain score (cm)* B a s e l i n e 6.4 ± 0.9 6.2 ± 1.0 Week 1 5.9 ± 1.1 3.6 ± 1.2 † ‡ Week 2 6.1 ± 1.2 3.3 ± 1.1 † ‡ Week 3 6.3 ± 1.1 2.5 ± 0.9 † ‡ § Activity score (cm)* B a s e l i n e 5.3 ± 0.9 5.2 ± 1.0 Week 1 5.7 ± 1.0 6.4 ± 0.8 † ‡ Week 2 5.9 ± 1.1 6.8 ± 0.9 † ‡ Week 3 6.0 ± 1.1 7.9 ± 1.0 † ‡ § Sleep score (cm)* B a s e l i n e 6.0 ± 1.5 5.8 ± 1.3 Week 1 6.9 ± 1.2 7.5 ± 0.9 † ‡ Week 2 6.7 ± 1.3 7.8 ± 0.8 † ‡ Week 3 6.6 ± 1.3 8.3 ± 0.7 † ‡ § Oral analgesics (pills/day) B a s e l i n e 3.1 ± 1.1 3.3 ± 1.3 Week 1 2.8 ± 0.9 2.2 ± 0.9 † ‡ Week 2 2.7 ± 1.0 2.0 ± 0.8 † ‡ Week 3 2.9 ± 0.8 1.3 ± 0.6 † ‡ § d e c reased the need for daily oral (nonopioid) analgesic medication during each of the 1st, 2nd, and 3rd weeks of tre a t m e n t (P 0.05), whereas sham treatments produced no significant change in the patients' use of oral analgesic medications (Fig. 2) . The overall reduction in the analgesic medication re q u i rement was significantly g reater with active (49 ± 19%) than with sham (14 ± 10%) PENS tre a t m e n t s . F i n a l l y, the poststudy evaluation of the two treatment modalities revealed that active PENS was clearly the pre f e rred therapy (92%) for alleviating the pain and numbness in the lower extremities. In addition, 88% of the patients re p o rted an i m p roved sense of well-being after PENS t reatment, and 92% of the patients e x p ressed a willingness to "pay extra money" for PENS therapy in the future. No side effects were re p o rted with either therapeutic modality.
Hamza and Associates
C O N C L U S I O N S -In this pro s p e c t i v e
c rossover sham-controlled study, PENS provided highly effective short -t e rm pain re l i e f for patients with diabetic peripheral neuro p a t h y. The beneficial effects of the active versus sham PENS treatments were re m a r kably similar before and after the cro s s o v e r t reatments were perf o rmed. However, a c a rry-over effect was evident from the prior PENS therapy, despite the 1-week re c o v e ry (washout) period, as evidenced by the lower overall baseline pain scores in the sham group (Table 2) . These findings supp o rt earlier publications that described the beneficial effects of electroanalgesic therapy in diabetes-induced neuropathic symptoms (6-8). In addition, the apparent cumulative benefits of PENS therapy over time suggest that this therapy may have long-term benefits consistent with the experimental findings of Mo et al. (17) involving electro a c u p u n ct u re and TENS in animals with experimental (drug-induced) diabetes and associated n e u ropathic changes.
Although the precise mechanism of PENS-induced analgesia is not known at this time, it appears to be related to both neural modulation (18) and an increase in endogenous opioid-like substances (e.g., dynorphins, endorphins, enkephalins) within the central nervous system (19). I n t e re s t i n g l y, both Cameron et al. (20) and Mo et al. (17) , have re p o rted that peripheral electrical stimulation can norm a l i z e the changes in nerve conduction velocity when using an experimental diabetic rat model. Walsh et al. (21) also observed a d e c rease in nerve conduction latency and mechanical pain threshold when TENS was applied directly over the nerve. In addition, clinical studies have suggested that the use of electrotherapy in diabetic patients produces decreases in mechanical pain thre s hold, a local vasodilatory effect, and enhanced wound healing (21-24).
Active PENS treatments produced significant pain relief, increased levels of mood and physical activity, and impro v e d quality of sleep compared with the sham t reatments during the course of the 3-week t reatment period. Improvements in activity level and sleep quality may be secondary to i m p roved pain control with PENS therapy. I n t e re s t i n g l y, pain relief appeared to be maximal at the end of the 3rd week of t reatment. However, within 1 week of the last PENS treatment session, the pain score s began to re t u rn to pre t reatment (baseline) levels. These data suggest that the use of PENS will re q u i re a maintenance tre a t m e n t p rogram to achieve a more sustained beneficial effect, which is consistent with the findings of Kumar and Marshall (6) , that involved using TENS to treat neuro p a t h i c pain. In the future, a randomized cro s s o v e r study involving PENS and TENS therapies in the management of diabetic neuro p a t h i c pain should be perf o rm e d .
P revious studies involving the use of PENS in patients with chronic pain synd romes showed that alternating low-and h i g h -f requency stimulation for 30-45 min p roduced the optimal analgesic eff e c t (25,26). There f o re, we chose to use stimulus f requencies of 15 and 30 Hz at 30-min intervals during each of the active PENS tre a tment sessions. Because the natural course of n e u ropathic symptoms is highly variable, these data supporting the short -t e rm benefits of PENS therapy must be interpre t e d with caution. To minimize investigator and patient bias, all assessments were perf o rm e d by a blinded observ e r, and the patients, none of whom had ever undergone acupuncture , w e re told that the needle-only (sham) tre a tments re p resented an acupuncture -l i k e t h e r a p y. Nevertheless, these pre l i m i n a ry data clearly re q u i re validation by a follow-up study that replicates these findings.
Although neuropathic pain is most commonly treated with a combination of a n t i d e p ressants, opioids, and nonopioid
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Electroanalgesia with PENS for neuropathic pain Pain score (cm) B a s e l i n e 5.2 ± 1.6 6.2 ± 1.3 † Week 1 4.6 ± 1.5 3.8 ± 1.2* Week 2 4.6 ± 1.4 3.5 ± 1.0* Week 3 4.8 ± 1.2 2.6 ± 0.9* ‡ § Activity score (cm) B a s e l i n e 5.9 ± 1.3 4.8 ± 1.2 † Week 1 6.4 ± 1.1 6.5± 0.8* Week 2 6.2 ± 1.3 7.0 ± 1.0* Week 3 6.3 ± 1.2 7.8 ± 1.1* ‡ § Sleep score (cm) B a s e l i n e 6.8 ± 1.5 5.7 ± 1.3 † Week 1
7.3 ± 1.3 7.5 ± 1.2* Week 2 7.0 ± 1.1 7.9 ± 1.0* Week 3 7.1 ± 1.2 8.6 ± 1.0* ‡ § S c o res are for pain, physical activity, and quality of sleep 24 h before receiving the first treatment (baseline) and at the end of the first, second, and third weeks of each treatment after completion of the c rossover study. Data are means ± SD. VASs (0 = minimal [lowest] to 10 = maximal [highest] . *Significantly diff e rent from the baseline (P 0 . 0 5 ) ; †significantly diff e rent from sham baseline (P 0 . 0 5 ) ; ‡significantly diff e rent from Week 1 (P 0 . 0 5 ) ; §significantly diff e rent from Week 2 (P 0 . 0 5 ) . Table 3 -P re t reatment (baseline) and post-treatment POMS scores for the active and sham PENS t reatments after completion of the crossover study B a s e l i n e After sham After active PENS Te n s i o n -a n x i e t y 54.6 ± 7.4 50.4 ± 7.1 44.1 ± 5.6 D e p re s s i o n -d e j e c t i o n 58.6 ± 9.4 56.1 ± 10.8 47.5 ± 7.2 A n g e r-h o s t i l i t y 62.9 ± 12.2 59.3 ± 12.1 51.1 ± 9.1 Vi g o r-a c t i v i t y 53.1 ± 6.1 50.6 ± 7.7 50.9 ± 12.4 F a t i g u e -i n e rt i a 56.1 ± 6.6 51.4 ± 6.8 43.3 ± 7.1* C o n f u s i o n -b e w i l d e rm e n t 53.5 ± 7.4 50.2 ± 8.3 44.4 ± 6.3* Total mood disturbance 71.3 ± 32.1 57.8 ± 34.4 29.5 ± 27.6* Data are means ± SD. *Significantly greater decrease from baseline values after active PENS (vs. sham) tre a t m e n t (P 0 . 0 1 ) .
analgesics, gastrointestinal side effects and excessive sedation can be problematic in patients with diabetes (27). Analogous to our earlier findings with PENS in chro n i c pain conditions (10,13), these data suggest that this form of electroanalgesia can significantly decrease a diabetic patient' s daily oral analgesic re q u i rements. The analgesic-sparing effects of PENS may also minimize the side effects of commonly used pharm a c ological agents. The improvements in post-tre a t m e n t SF-36 and mood levels (as assessed by the BDI and POMS questionnaires) suggest that the beneficial effects of PENS may also be related to an antidepressant action. These psychological data further support the clinical utility of PENS as a nonpharm a c o l o g ical treatment modality in this patient population. After completing the cro s s o v e r s t u d y, these patients also re p o rted that PENS produced an improved sense of wellbeing, and most patients expressed a willingness to pay additional money (out of pocket) to receive PENS therapy in the f u t u re. Many of the patients have elected to continue with PENS treatments on a less f requent basis as part of a maintenance therapy program. The need for further tre a tments to maintain the beneficial effects of PENS therapy is consistent with the findings for other forms of electrotherapy in this patient population (6,7).
The deficiencies of the study design include: 1) the possibility of patient bias as a result of our inability to perf o rm the study in a double-blind fashion because we could not "blind" the patients re g a rding the electrical sensation; 2) the failure to monitor serial blood glucose and glycated hemoglobin levels and nerve conduction velocities; and 3) the decrease in the beneficial e ffects of PENS over time will necessitate a maintenance treatment program to achieve a sustained effect. Long-term outcome studies are needed to ascertain the cumulative effects of PENS in this patient population. Comparative studies involving PENS and other forms of electro a n a l g e s i c therapy (e.g., TENS, electro a c u p u n c t u re ) and interaction studies involving pharm acological modalities (28) should be perf o rmed in the future. Although clearly less invasive than spinal cord stimulation, PENS is more complex than TENS.
In conclusion, PENS therapy pro d u c e s s h o rt -t e rm pain relief; improves mood, funct i o n a l i t y, and quality of sleep; and decre a s e s the oral nonopioid analgesic re q u i rements in patients with painful peripheral diabetic n e u ro p a t h y. However, PENS should be viewed as a supplementary (or complement a ry) therapy rather than as an alternative to conventional pharmacological therapy.
